Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12

Journal of Immunology

Volumn 178, Issue 12, 2007, Pages 7571-7580

  Kaiga, Teruo ^a,b   Sato, Marimo ^a   Kaneda, Hide ^a,b   Iwakura, Yoichiro ^a   Takayama, Tadatoshi ^b   Tahara, Hideaki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 23; PLASMID DNA; PROTEIN P19; PROTEIN P40;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG POTENCY; ELECTROPORATION; FEMALE; FIBROSARCOMA; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; KNOCKOUT GENE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL;

EID: 34250164929     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.12.7571     Document Type: Article

References (37)

1. Bennett, S. R., R. F. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic T cell responses is mediated by CD40 signalling. Nature 393: 478-480.
2. Schoenberger, S. P., R. E. Toes, E. I. Van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
3. + T helper and a T killer cell. Nature 393: 474-477.
4. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J. Immunol. 165: 6047-6055.
5. + T cells. J. Exp. Med. 197: 985-995.
6. Weaver, C. T., L. E. Harrington, P. R. Mangan, M. Gavrieli, and K. M. Murphy. 2006. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24: 677-688.
7. Scott, P. 1993. IL-12: initiation cytokine for cell-mediated immunity. Science 260: 496-497.
8. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunily. Nat. Rev. Immunol. 3: 133-146.
9. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen specific adaptive immunity. Annu. Rev. Immunol. 13: 251-276.
10. Atkins, M. B., M. J. Robertson, M. Gordon, M. T. Lotze, M. DeCoste, J. S. DuBois, J. Ritz, A. B. Sandler, H. D. Edington, P. D. Garzone, et al. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3: 409-417.
11. Bajetta, E., M. Del Vecchio, R. Mortarini, R. Nadeau, A. Rakhit, L. Rimassa, C. Fowst, A. Borri, A. Anichini, and G. Parmiani. 1998. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin. Cancer Res. 4: 75-85.
12. Coughlin, C. M., M. Wysocka, G. Trinchieri, and W. M. Lee. 1997. The effect of interleukin 12 desensitization on the antitumor efficacy of recombinant interleukin 12. Cancer Res. 57: 2460-2467.
13. Lankford, C. S., and D. M. Frucht. 2003. A unique role for IL-23 in promoting cellular immunity. J. Leukocyte Biol. 73: 49-56.
14. Belladonna, M. L., J. C. Renauld, R. Bianchi, C. Vacca, F. Fallarino, C. Orabona, M. C. Fioretti, U. Grohmann, and P. Puccetti. 2002. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J. Immunol. 168: 5448-5454.
15. Watford, W. T., B. D. Hissong, J. H. Bream, Y. Kanno, L. Muul, and J. J. O'Shea. 2004. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol. Rev. 202: 139-156.
16. Langrish, C. L., B. S. McKenzie, N. J. Wilson, R. de Waal Malefyt, R. A. Kastelein, and D. J. Cua. 2004. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol. Rev. 202: 96-105.
17. Parham, C. M. Chirica, J. Timans, E. Vaisberg, M. Travis, J. Cheung, S. Pflanz, R. Zhang, K. P. Singh, F. Vega, et al. 2002. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168: 5699-5708.
18. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6: 1123-1132.
19. Park, H., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. H. Wang, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inllammation by producing interleukin 17. Nat. Immunol. 6: 1133-1141.
20. Dong, C. 2006. Diversification of T helper cell lineages: finding the family root of IL-17-producing cells. Nat. Rev. Immunol. 6: 329-333.
21. Yen, D., J. Cheung, H. Scheerens, F. Poulet, T. McClanahan, B. Mckenzie, M. A. Kleinschek, A. Owyang, J. Mattson, W. Blumenschein, et al. 2006. IL-23 is essential for T cell-mediated colitis and promotes inllammation via IL-17 and IL-6. J. Clin. Invest. 116: 1310-1316.
22. Chen, Y., C. L. Langrish, B. Mckenzie, B. Joyce-Shaikh, J. S. Stumhofer, T. McClanahan, W. Blumenschein, T. Churakovsa, J. Low, L. Presta, et al. 2006. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 116: 1317-1326.
23. Kullberg, M. C., D. Jankovic, C. G. Feng, S. Hue, P. L. Gorclick, B. S. McKenzie, D. J. Cua, F. Powrie, A. W. Cheever, K. J. Maloy, and A. Sher. 2006. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J. Exp. Med. 203: 2485-2294.
24. Langowski, J. L., X. Zhang, L. Wu, J. D. Mattson, T. Chen, K. Smith, B. Basham, T. McClanahan, R. A. Kastelein, and M. Oft. 2006. IL-23 promotes tumour incidence and growth. Nature 442: 461-466.
25. Ugai, S., O. Shimozato, L. Yu, Y. Q. Wang, K. Kawamura, H. Yamamoto, T. Yamaguchi, H. Saisho, S. Sakiyama, and M. Tagawa. 2003. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther. 10: 771-778.
26. Wang, Y. Q., S. Ugai, O. Shimozato, L. Yu, K. Kawamura, H. Yamamoto, T. Yamaguchi, H. Saisho, and M. Tagawa. 2003. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int. J. Cancer 105: 820-824.
27. Lo, C. H., S. C. Lee, P. Y. Wu, W. Y. Pan, J. Su, C. W. Cheng, S. R. Roffler, B. L. Chiang, C. N. Lee, C. W. Wu, and M. H. Tao. 2003. Antitumor and antimetastatic activity of IL-23. J. Immunol. 171: 600-607.
28. Overwijk, W. W., K. E. Visser, F. H. Tirion, L. A. Jong, T. W. H. Pols, Y. U. Velden, J. G. Boorn, A. M. Keller, W. A. Buurman, M. R. Theoret, et al. 2006. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J. Immunol. 176: 5213-5222.
29. Oppmann, B., R. Lesley, B. Blom, J. C. Timans, Y. Xu, B. Hunte, F. Vega, N. Yu, J. Wang, K. Singh, et al. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725.
30. Shimao, K., T. Takayama, K. Enomoto, T. Saito, S. Nagai, J. Miyazaki, K. Ogawa, and H. Tahara. 2005. Cancer gene therapy using in vivo electroporation of Flt3-ligand. Int. J. Oncol. 27: 457-463.
31. Nakahara, S., T. Tsunoda, T. Baba, S. Asabe, and H. Tahara. 2003. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 63: 4112-4118.
32. Yahata, T., K. Watanabe, A. Ohta, Y. Ohmi, N. Sato, K. Santa, N. Abe, K. Iwakabe, S. Kaneko, N. Suzuki, et al. 1998. Accumulation of IL-12-activated antitumor effector cells into lymph nodes of tumor-bearing mice. Immunol. Lett. 61: 127-133.
33. Aggarwal, S., N. Ghilardi, M. H. Xie, F. J. de Sauvage, and A. L. Gurney. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278: 1910-1914.
34. Berman, R. M., T. Suzuki, H. Tahara, P. D. Robbins, S. K. Narula, and M. T. Lotze. 1996. Systemic administration of cellular IL-10 induces and effective, specific, and long-lived immune response against established tumors in mice. J. Immunol. 157: 231-238.
35. Takayama, T., H. Tahara, and A. W. Thomson. 2001. Differential effects of myeloid dendritic cells retrovirally transduced to express mammalian or viral IL-10 on CTL and NK cell functions and resistance to tumor growth. Transplantation 71: 1334-1340.
36. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, and W. J. Storkus. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153: 1697-1706.
37. Bettelli, E., Y. Carrier, W. Gao, T. Korn, T. B. Strom, M. Oukka, H. L. Weiner, and V. K. Kuchroo. 2006. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature 441: 235-238.